IV insulin
PreclinicalSmall molecule
IV insulin is one of 8 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Diabetic Ketoacidosis
#DrugCompanyPhaseTrials
1Reamberin
PPOLYSAN Scientific & Technological Pharmaceutical Company
Phase 3
Jardiance
Boehringer IngelheimPreclinical
Glargine
Eli LillyPreclinical
DPP-4 Inhibitors
Boehringer IngelheimPreclinical
Degludec
Eli LillyPreclinical
Sodiumchloride
RRadboud University Medical Center
Preclinical
IV insulin
RRush University Medical Center
Preclinical
IV Fluid Repletion
UUniversity of Maryland, Baltimore
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IV insulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRush University Medical Center